Page 1397 - Williams Hematology ( PDFDrive )

1372 Part X: Malignant Myeloid Diseases <CN>: Myelodysplastic Syndromes PB

569. Robak T, Szmigielska-Kaplon A, Urbanska-Rys H, et al: Efficacy and toxicity of low- 575. Bryan J, Kantarjian H, Prescott H, Jabbour E: Clofarabine in the treatment of myelodys-
dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multi- plastic syndromes. Expert Opin Investig Drugs 23(2):255–263, 2014.
lineage dysplasia. Neoplasma 50(3):172–175, 2003. 576. Walter MJ, Shen D, Ding L, et al: Clonal architecture of secondary acute myeloid
570. Mario AD, Pagano L, Mele L, et al: Use of gemcitabine (GEM) in advanced myelodys- leukemia. N Engl J Med 366(12):1090–1098, 2012.
plastic syndromes. Ann Oncol 12(10):1494, 2001. 577. Steensma DP: Dysplasia has a differential diagnosis: Distinguishing genuine myelo-
571. Ribrag V, Suzan F, Ravoet C, et al: Phase II trial of CPT-11 in myelodysplastic syn- dysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr
dromes with excess of marrow blasts. Leukemia 17(2):319–322, 2003. Hematol Malig Rep 7(4):310–320, 2012.
572. Giles FJ, Faderl S, Thomas DA, et al: Randomized phase I/II study of troxacitabine 578. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organi-
combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid zation (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and
leukemias. J Clin Oncol 21(6):1050–1056, 2003. important changes. Blood 114(5):937–951, 2009.
573. Giles FJ, Garcia-Manero G, Cortes JE, et al: Phase II study of troxacitabine, a novel 579. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating
dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088, 1997.
20(3):656–664, 2002.
574. Bouabdallah R, Lefrere F, Rose C, et al: A phase II trial of induction and consolida-
tion therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk
elderly patients. Leukemia 13(10):1491–1496, 1999.

Kaushansky_chapter 87_p1341-1372.indd 1372 9/21/15 11:06 AM